STAAR Surgical Company reaffirmed sales guidance for the year 2022. For the year, the company reaffirming previously provided outlook for fiscal 2022 net sales of approximately $295 million, which takes into account a significant currency headwind and a continuation of the current level of COVID-19 related challenges in China and elsewhere, offset by stronger than expected demand for EVO lenses, which has continued through the beginning of the third quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.94 USD | -0.53% | -3.69% | +31.18% |
05-08 | Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating | MT |
05-08 | Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.18% | 2.02B | |
-7.38% | 181B | |
-0.46% | 108B | |
-6.98% | 66.12B | |
+2.65% | 50.65B | |
+5.27% | 43.11B | |
+3.49% | 40.74B | |
+19.92% | 31.6B | |
+16.38% | 25.56B | |
-7.00% | 24.16B |
- Stock Market
- Equities
- STAA Stock
- News STAAR Surgical Company
- STAAR Surgical Company Re-Affirms Sales Guidance for the Year 2022